{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:15:45Z","timestamp":1783509345601,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["82425002"],"award-info":[{"award-number":["82425002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370223"],"award-info":[{"award-number":["82370223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01413-1","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:18:55Z","timestamp":1775827135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Fengmei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1413_CR1","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134\u20134140 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1413_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1413_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1413_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"1413_CR5","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie, C. et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J. Clin. Oncol. 39, 3352\u20133363 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1413_CR6","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1413_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/blood.2020009515","volume":"138","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn, K. et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood 138, 531\u2013543 (2021).","journal-title":"Blood"},{"key":"1413_CR8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah, N. N. et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J. Clin. Oncol. 39, 1650\u20131659 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1413_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch, T. W. et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J. Clin. Oncol. 41, 1664\u20131669 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1413_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","volume":"20","author":"TW Laetsch","year":"2019","unstructured":"Laetsch, T. W. et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 20, 1710\u20131718 (2019).","journal-title":"Lancet Oncol."},{"key":"1413_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"1413_CR13","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"1413_CR14","doi-asserted-by":"publisher","unstructured":"Song, F. et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J. Immunotherapy Cancer 11, https:\/\/doi.org\/10.1136\/jitc-2022-005701 (2023).","DOI":"10.1136\/jitc-2022-005701"},{"key":"1413_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss, I. et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am. J. Hematol. 92, 858\u2013865 (2017).","journal-title":"Am. J. Hematol."},{"key":"1413_CR16","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493\u20132498 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1413_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"52","author":"S Raponi","year":"2011","unstructured":"Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. lymphoma 52, 1098\u20131107 (2011).","journal-title":"Leuk. lymphoma"},{"key":"1413_CR18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740\u2013753 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1413_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"1413_CR20","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","volume":"33","author":"J Pan","year":"2019","unstructured":"Pan, J. et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33, 2854\u20132866 (2019).","journal-title":"Leukemia"},{"key":"1413_CR21","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","volume":"9","author":"I Aldoss","year":"2025","unstructured":"Aldoss, I. et al. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 9, 2159\u20132172 (2025).","journal-title":"Blood Adv."},{"key":"1413_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","volume":"7","author":"AJ Lamble","year":"2023","unstructured":"Lamble, A. J. et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 7, 575\u2013585 (2023).","journal-title":"Blood Adv."},{"key":"1413_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 137, 323\u2013335 (2021).","journal-title":"Blood"},{"key":"1413_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea, M. et al. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 11, 874\u2013899 (2021).","journal-title":"Cancer Discov."},{"key":"1413_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey, N. V. et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J. Clin. Oncol. 38, 415\u2013422 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1413_CR26","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","volume":"36","author":"E Pennesi","year":"2022","unstructured":"Pennesi, E. et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia 36, 1516\u20131524 (2022).","journal-title":"Leukemia"},{"key":"1413_CR27","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","volume":"27","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian, H. M. et al. Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin. Cancer Res. 27, 2742\u20132754 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1413_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani, D. et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia 33, 884\u2013892 (2019).","journal-title":"Leukemia"},{"key":"1413_CR29","doi-asserted-by":"publisher","unstructured":"Zhao, Y. et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood, https:\/\/doi.org\/10.1182\/blood.2024023930 (2024).","DOI":"10.1182\/blood.2024023930"},{"key":"1413_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hon.2672","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma, F. et al. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematol. Oncol. 37, 601\u2013608 (2019).","journal-title":"Hematol. Oncol."},{"key":"1413_CR31","unstructured":"Therneau, T. M., Crowson, C. S. & Atkinson, E. J. Adjusted Survival Curves. survival package vignette, CRAN. https:\/\/cran.r-project.org\/web\/packages\/survival\/vignettes\/adjcurve.pdf (2015)."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01413-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01413-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01413-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:24:07Z","timestamp":1783506247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01413-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01413-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}